Curaleaf Takes Full Control of Germany’s Four 20 Pharma to Bolster European Cannabis Platform

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Curaleaf Holdings ( (TSE:CURA) ) has shared an update. Curaleaf Holdings, Inc., a major international provider of cannabis consumer products, has deep operations across Europe, Canada, and Australasia, where it combines scientific research with tightly controlled cultivation and production. Through its portfolio of brands and vertically integrated supply chain, the company targets both medical and adult-use markets, supplying regulated channels including pharmacies, nursing homes, and research institutions. On April 30, 2026, Curaleaf said it had completed the buyout of the remaining 45% stake in Germany’s Four 20 Pharma GmbH, giving it full ownership of the EU-GMP and GDP licensed medical cannabis producer and distributor. The deal consolidates Curaleaf’s control over a key German and European asset, bolstering its seed-to-patient supply chain from Portugal and Canada into Germany, accelerating brand expansion into markets such as the U.K. and Poland, and reinforcing its strategy of pairing local expertise with global scale for stakeholders across Europe’s fast-growing medical cannabis market. Curaleaf highlighted that Four 20 Pharma, founded to ensure continuous patient care and known for its “420NATURAL” brand, brings high-quality cultivation, pharmaceutical-grade processing, and strong regulatory credentials. Making Four 20 Pharma a fully integrated subsidiary is intended to deepen Curaleaf’s presence in Germany, enhance patient access to medical cannabis, and further entrench the company as a standard-setter in regulated cannabis markets worldwide. The most recent analyst rating on (TSE:CURA) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on Curaleaf Holdings stock, see the TSE:CURA Stock Forecast page. Spark’s Take on CURA Stock According to Spark, TipRanks’ AI Analyst, CURA is a Neutral. The score is held back primarily by weak profitability and margin pressure despite improving cash generation, while technicals are supportive with price above major moving averages and positive momentum. The latest earnings call was mixed—operational progress and refinancing improvements were tempered by ongoing price compression, higher cost structure, expensive leverage, and near-term revenue softness. To see Spark’s full report on CURA stock, click here. More about Curaleaf Holdings Curaleaf Holdings, Inc. is a leading international cannabis company that provides consumer products across both medical and adult-use markets. The firm operates a vertically integrated model, combining cultivation, extraction, production, and distribution, with a presence spanning Europe, Canada, and Australasia under brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem. Curaleaf focuses on delivering pharmaceutical-grade quality and reliable access to cannabis products, supported by pioneering science and research. Its international arm leverages a broad distribution network and regulatory expertise to serve pharmacies, nursing homes, research institutions, and other regulated channels, positioning the company as a key player in the global medical cannabis ecosystem. Average Trading Volume: 766,788 Technical Sentiment Signal: Buy Current Market Cap: C$3.45B See more insights into CURA stock on TipRanks’ Stock Analysis page.